Marty Makary

And does it also mean that once I've got a system that works, I can use it for different indications and maybe help understand a little bit about where this goes?

Because there's many patients

Because there's many patients

that today are looking at papers on cell and gene therapies, early data, and they're saying, when can I get access?

that today are looking at papers on cell and gene therapies, early data, and they're saying, when can I get access?

I'm at risk.

I'm at risk.

This matters a lot to patients.

This matters a lot to patients.

And maybe you can help contextualize how this translates into speed and access.

And maybe you can help contextualize how this translates into speed and access.

Right.

Right.

And what about for CAR T therapy?

And what about for CAR T therapy?

So there's this blossoming class of therapeutics in CAR T that's historically been used exclusively for oncology, for cancer, increasing discussion about using it for autoimmune conditions.

So there's this blossoming class of therapeutics in CAR T that's historically been used exclusively for oncology, for cancer, increasing discussion about using it for autoimmune conditions.

Does this help with the CAR T therapy pathway and enabling faster routes to market and more access and lower cost?

Does this help with the CAR T therapy pathway and enabling faster routes to market and more access and lower cost?

And just for folks to understand when they take T cells, edit them and put them back in the body and those T cells go after targets in the body and destroy those targets and many blood cancers are now seeing extraordinary results with these CAR T therapies and now they're going after autoimmune conditions.